Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MEN1 | O00255 | 11/20 | 0.68 |
| ▸ | KMT2A | Q03164 | 11/20 | 0.68 |
| ▸ | CYP3A4 | P08684 | 10/20 | 0.68 |
| ▸ | HSD17B10 | Q99714 | 8/20 | 0.68 |
| ▸ | CYP2C9 | P11712 | 8/20 | 0.68 |
| ▸ | ALOX15 | P16050 | 8/20 | 0.68 |
| ▸ | KDM4E | B2RXH2 | 8/20 | 0.68 |
| ▸ | FTO | Q9C0B1 | 7/20 | 0.68 |
| ▸ | MAPT | P10636 | 7/20 | 0.68 |
| ▸ | ABCB1 | P08183 | 7/20 | 0.68 |
| ▸ | TP53 | P04637 | 7/20 | 0.68 |
| ▸ | ALDH1A1 | P00352 | 6/20 | 0.68 |
| ▸ | HPGD | P15428 | 6/20 | 0.68 |
| ▸ | CYP1A2 | P05177 | 6/20 | 0.68 |
| ▸ | CYP2D6 | P10635 | 6/20 | 0.68 |
| ▸ | CYP2C19 | P33261 | 6/20 | 0.68 |
| ▸ | CYP1B1 | Q16678 | 6/20 | 0.68 |
| ▸ | XDH | P47989 | 5/20 | 0.68 |
| ▸ | CYP1A1 | P04798 | 5/20 | 0.68 |
| ▸ | APP | P05067 | 5/20 | 0.68 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Quercetin SCHEMBL6042686 | 0.93 | MEN1 (0.71) | MEN1KMT2ACYP3A4HSD17B10CYP2C9 | |
| Kaempferol SCHEMBL31164054 | 0.90 | MEN1 (0.79) | MEN1KMT2ACYP3A4HSD17B10CYP2C9 | |
| Kaempferol SCHEMBL1485787 | 0.90 | MEN1 (0.79) | MEN1KMT2ACYP3A4HSD17B10CYP2C9 | |
| Morin SCHEMBL2118429 | 0.88 | MEN1 (0.75) | MEN1KMT2ACYP3A4HSD17B10CYP2C9 | |
| Galangin SCHEMBL7926038 | 0.86 | MEN1 (0.85) | MEN1KMT2ACYP3A4HSD17B10CYP2C9 | |
| Quercetin SCHEMBL111510 | 0.85 | MEN1 (0.76) | MEN1KMT2ACYP3A4HSD17B10CYP2C9 | |
| Datiscetin SCHEMBL15675904 | 0.84 | MEN1 (0.75) | MEN1KMT2ACYP3A4HSD17B10CYP2C9 | |
| Morin SCHEMBL5248628 | 0.83 | MEN1 (0.89) | MEN1KMT2ACYP3A4HSD17B10CYP2C9 | |
| Quercetin SCHEMBL729498 | 0.83 | MEN1 (0.76) | MEN1KMT2ACYP3A4HSD17B10CYP2C9 | |
| Kaempferol SCHEMBL29378805 | 0.82 | MEN1 (1.00) | MEN1KMT2ACYP3A4HSD17B10CYP2C9 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 28 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20140162986-A1 | Methods for treatment of thiol-containing compound deficient conditions | NATIONAL JEWISH MEDICAL AND RESEARCH CENTER (US) | 2014-06-12 | — | — | US | disclosed |
| US-8138158-B2 | Compositions and methods for therapy for diseases characterized by defective chloride transport | CHILDREN'S HOSPITAL & RESEARCH CENTER AT OAKLAND (US) | 2012-03-20 | — | — | US | disclosed |
| US-20110288161-A1 | METHODS FOR TREATMENT OF THIOL-CONTAINING COMPOUND DEFICIENT CONDITIONS | NATIONAL JEWISH MEDICAL AND RESEARCH CENTER | 2011-11-24 | — | — | US | disclosed |
| US-20110104305-A1 | COMPOUNDS AND METHODS FOR THIOL-CONTAINING COMPOUND EFFLUX AND CANCER TREATMENT | DAY BRIAN J | 2011-05-05 | — | — | US | disclosed |
| US-20100286256-A1 | COMPOSITIONS AND METHODS FOR THERAPY FOR DISEASES CHARACTERIZED BY DEFECTIVE CHLORIDE TRANSPORT | NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT | 2010-11-11 | — | — | US | disclosed |
| US-7790762-B2 | Compounds and methods for thiol-containing compound efflux and cancer treatment | NATIONAL JEWISH HEALTH (US) | 2010-09-07 | — | — | US | disclosed |
| EP-2217259-A2 | METHODS FOR TREATMENT OF THIOL-CONTAINING COMPOUND DEFICIENT CONDITIONS | National Jewish Health (US) | 2010-08-18 | — | — | EP | disclosed |
| US-7718694-B2 | Compositions and methods for therapy for diseases characterized by defective chloride transport | CHILDREN'S HOSPITAL & RESEARCH CENTER AT OAKLAND (US) | 2010-05-18 | — | — | US | disclosed |
| EP-1562563-B1 | METHODS FOR TREATMENT OF THIOL-CONTAINING COMPOUND DEFICIENT CONDITIONS | NAT JEWISH HEALTH (US) | 2010-03-03 | — | — | EP | disclosed |
| WO-2009052411-A2 | METHODS FOR TREATMENT OF THIOL-CONTAINING COMPOUND DEFICIENT CONDITIONS | NATIONAL JEWISH MEDICAL AND RESEARCH CENTER (US) | 2009-04-23 | — | — | WO | disclosed |
| EP-1562563-A2 | METHODS FOR TREATMENT OF THIOL-CONTAINING COMPOUND DEFICIENT CONDITIONS | National Jewish Medical and Research Center (US) | 2005-08-17 | — | — | EP | disclosed |
| US-20040197272-A1 | Compositions and methods for therapy for diseases characterized by defective chloride transport | CHILDREN'S HOSPITAL OAKLAND (US) | 2004-10-07 | — | — | US | disclosed |
| WO-2004042020-A2 | METHODS FOR TREATMENT OF THIOL-CONTAINING COMPOUND DEFICIENT CONDITIONS | NATIONAL JEWISH MEDICAL AND RESEARCH CENTER (US) | 2004-05-21 | — | — | WO | disclosed |
| US-20040087527-A1 | Cystic fibrosis therapy; ATP-binding cassette transport modulation; glutathione concentration in epithelial lining fluid of lower respiratory tract | NATIONAL JEWISH MEDICAL AND RESEARCH CENTER | 2004-05-06 | — | — | US | disclosed |
| US-20030096762-A1 | Compositions and methods for cystic fibrosis therapy | CHILDREN'S HOSPITAL OAKLAND | 2003-05-22 | — | — | US | disclosed |
| US-6329422-B1 | ENHANCING, STIMULATING CHLORIDE TRANSPORT IN EPITHELIAL CELLS; FLAVONE OR ISOFLAVONE OR A STEREOISOMER THEREOF. | CHILDREN'S HOSPITAL OAKLAND RESEARCH INSTITUTE | 2001-12-11 | — | — | US | disclosed |
| WO-2001080855-A1 | TELOMERASE INHIBITORS AND METHODS OF THEIR USE | GERON CORPORATION (US) | 2001-11-01 | — | — | WO | disclosed |
| EP-1024803-A1 | FLAVONOIDS FOR CYSTIC FIBROSIS THERAPY | Children's Hospital Medical Center of Northern California (US) | 2000-08-09 | — | — | EP | disclosed |
| US-5972995-A | ONE OR MORE FLAVONES AND/OR ISOFLAVONES CAPABLE OF STIMULATING CHLORIDE TRANSPORT IN EPITHELIAL TISSUES. | CHILDREN'S HOSPITAL MEDICAL CENTER OF NORTHERN CALIFORNIA (US) | 1999-10-26 | — | — | US | disclosed |
| WO-1999018953-A1 | FLAVONOIDS FOR CYSTIC FIBROSIS THERAPY | CHILDREN'S HOSPITAL MEDICAL CENTER OF NORTHERN CALIFORNIA (US) | 1999-04-22 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040087527-A1 | Cystic fibrosis therapy; ATP-binding cassette transport modulation; glutathione concentration in epithelial lining fluid of lower respiratory tract | ABCC1, CFTR, ABCC2 | MEN1 4736/4885KMT2A 4502/4885CYP3A4 1454/4885 |
| US-20040197272-A1 | Compositions and methods for therapy for diseases characterized by defective chloride transport | SLC26A3, CFTR, SLC26A4 | MEN1 3062/4885KMT2A 4655/4885CYP3A4 2107/4885 |
| US-20100286256-A1 | COMPOSITIONS AND METHODS FOR THERAPY FOR DISEASES CHARACTERIZED BY DEFECTIVE CHLORIDE TRANSPORT | SLC26A3, CFTR, SLC26A4 | MEN1 3062/4885KMT2A 4655/4885CYP3A4 2107/4885 |
| US-20110288161-A1 | METHODS FOR TREATMENT OF THIOL-CONTAINING COMPOUND DEFICIENT CONDITIONS | ABCC1, SLC47A2, SLC47A1 | MEN1 4788/4885KMT2A 2544/4885CYP3A4 2404/4885 |
| US-20140162986-A1 | Methods for treatment of thiol-containing compound deficient conditions | ABCC1, CFTR, SLC47A1 | MEN1 4239/4885KMT2A 4390/4885CYP3A4 2536/4885 |
| US-20030096762-A1 | Compositions and methods for cystic fibrosis therapy | CFTR, SLC26A3, CLCN2 | MEN1 3451/4885KMT2A 4726/4885CYP3A4 2013/4885 |
| US-20110104305-A1 | COMPOUNDS AND METHODS FOR THIOL-CONTAINING COMPOUND EFFLUX AND CANCER TREATMENT | ABCC1, ABCC2, ABCB1 | MEN1 4218/4885KMT2A 4011/4885CYP3A4 1242/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.